52 mg左炔诺孕酮宫内缓释系统与双极射频非宫腔镜子宫内膜消融术治疗月经过多的比较:多中心随机对照试验长期随访
本研究为MIRA多中心随机对照试验的长期随访,比较起始采用52 mg左炔诺孕酮宫内缓释系统(n=132)或双极射频非宫腔镜子宫内膜消融术(n=138)治疗月经过多女性的再干预风险与月经失血量。平均随访7.4年,196例参与。总体再干预率两组无显著差异,但左炔诺孕酮组手术再干预率显著更高,子宫切除术率两组相似。两种策略长期均有效降低月经失血量。
要点
- 长期随访总体再干预率左炔诺孕酮组40.0% vs 消融组28.7%,无显著差异(RR 1.39,95%CI 0.92-2.10)。
- 手术再干预率左炔诺孕酮组35.3% vs 消融组19.1%,左炔诺孕酮组显著更高(RR 1.84,95%CI 1.11-3.10)。
- 子宫切除术率左炔诺孕酮组11.8% vs 消融组18.1%,无显著差异(RR 0.65,95%CI 0.32-1.34)。
核心结论
- 长期随访中,起始采用52 mg左炔诺孕酮宫内缓释系统与起始采用双极射频非宫腔镜子宫内膜消融术的女性总体再干预风险无差异。
- 分配至左炔诺孕酮组的女性手术再干预风险更高,后续子宫内膜消融术增加是主要原因。
- 两种治疗策略长期均有效降低月经失血量。
研究设计与样本
- 本研究为多中心随机对照试验(MIRA trial)的长期随访研究。
- 原试验将女性分配至52 mg左炔诺孕酮宫内缓释系统组(n=132)或双极射频非宫腔镜子宫内膜消融术组(n=138)。
- 原试验270例随机女性中,196例参与长期随访(左炔诺孕酮组n=94,消融组n=102)。
- 平均随访时长7.4年(范围6-9年)。
主要发现
- 累积再干预率(含药物和手术再干预)左炔诺孕酮组为40.0%(34/85),消融组为28.7%(27/94),相对风险1.39(95%CI 0.92-2.10)。
- 累积手术再干预率左炔诺孕酮组为35.3%(30/85),消融组为19.1%(18/94),相对风险1.84(95%CI 1.11-3.10)。
- 子宫切除术率左炔诺孕酮组为11.8%(10/94),消融组为18.1%(17/102),相对风险0.65(95%CI 0.32-1.34)。
- 大多数再干预发生在随访的前24个月内。
- 共171份Pictorial Blood Loss Assessment Chart评分显示中位出血评分为0.0。
临床怎么用
- 长期随访结果可支持医生优化对月经过多女性的咨询,促进关于治疗选择的知情决策。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The symptom of heavy menstrual bleeding has a substantial impact on professional, physical, and social functioning. In 2021, results from a randomized controlled trial comparing a 52-mg levonorgestrel-releasing intrauterine system and radiofrequency nonresectoscopic endometrial ablation as treatments for women with heavy menstrual bleeding were published. Both treatment strategies were equally effective in treating heavy menstrual bleeding during 2-year follow-up. However, long-term results are also relevant for both patients and healthcare providers. OBJECTIVE: This study aimed to assess long-term differences in reintervention risk and menstrual blood loss in women with the symptom of heavy menstrual bleeding treated according to a strategy starting with a 52-mg levonorgestrel-releasing intrauterine system or radiofrequency nonresectoscopic endometrial ablation. STUDY DESIGN: This study was a long-term follow-up study of a multicenter randomized controlled trial (MIRA trial), in which women were allocated to either a 52-mg levonorgestrel-releasing intrauterine device (n=132) or radiofrequency nonresectoscopic endometrial ablation (n=138). Women from the original trial were contacted to fill out 6 questionnaires. The primary outcome was the reintervention rate after allocated treatment. Secondary outcomes included surgical reintervention rate, menstrual bleeding measured by the Pictorial Blood Loss Assessment Chart, (disease-specific) quality of life, sexual function, and patient satisfaction. RESULTS: From the 270 women who were randomized in the original trial, 196 (52-mg levonorgestrel-releasing intrauterine system group: n=94; radiofrequency nonresectoscopic endometrial ablation group: n=102) participated in this long-term follow-up study. Mean follow-up duration was 7.4 years (range, 6-9 years). The cumulative reintervention rate (including both medical and surgical reinterventions) was 40.0% (34/85) in the 52-mg levonorgestrel-releasing intrauterine system group and 28.7% (27/94) in the radiofrequency nonresectoscopic endometrial ablation group (relative risk, 1.39; 95% confidence interval, 0.92-2.10). The cumulative rate of surgical reinterventions only was significantly higher among patients with a treatment strategy starting with a 52-mg levonorgestrel-releasing intrauterine system compared with radiofrequency nonresectoscopic endometrial ablation (35.3% [30/85] vs 19.1% [18/94]; relative risk, 1.84; 95% confidence interval, 1.11-3.10). However, the hysterectomy rate was similar (11.8% [10/94] in the 52-mg levonorgestrel-releasing intrauterine system group and 18.1% [17/102] in the radiofrequency nonresectoscopic endometrial ablation group; relative risk, 0.65; 95% confidence interval, 0.32-1.34). Most reinterventions occurred during the first 24 months of follow-up. A total of 171 Pictorial Blood Loss Assessment Chart scores showed a median bleeding score of 0.0. No clinically relevant differences were found regarding quality of life, sexual function, and patient satisfaction. CONCLUSION: The overall risk of reintervention after long-term follow-up was not different between women treated according to a treatment strategy starting with a 52-mg levonorgestrel-releasing intrauterine system and those treated using a strategy starting with radiofrequency nonresectoscopic endometrial ablation. However, women allocated to a treatment strategy starting with a 52-mg levonorgestrel-releasing intrauterine system had a higher risk of surgical reintervention, which was driven by an increase in subsequent endometrial ablation. Both treatment strategies were effective in lowering menstrual blood loss over the long term. The results of this long-term follow-up study can support physicians in optimizing the counseling of women with heavy menstrual bleeding, thus promoting informed decision-making regarding choice of treatment.
引用
- Huijs DPC, Derickx AJM, Beelen P, et al. A 52-mg levonorgestrel-releasing intrauterine system vs bipolar radiofrequency nonresectoscopic endometrial ablation in women with heavy menstrual bleeding: long-term follow-up of a multicenter randomized controlled trial. Am J Obstet Gynecol. 2024. PMID: 38280433. doi:10.1016/j.ajog.2024.01.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。